The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Rationale for Phase III PROSPECT Trial in Prostate Cancer

Nicholas J. Vogelzang, MD
Published Online:5:44 PM, Tue June 12, 2018

Nicholas J. Vogelzang, MD, a medical oncologist at the Comprehensive Cancer Centers of Nevada, discusses the rationale behind conducting the PROSPECT trial in patients with relapsed prostate cancer. Patients enrolled in this study had prostate cancer return after hormonal ablation.

The idea was to stimulate the immune system with a vaccine containing 3 pieces of the prostate cancer. When patients relapse after 1 to 3 years with prostate cancer, the prostate-specific antigen (PSA) often increases, Vogelzang explains. Researchers hypothesized that if you could stimulate the immune system with the virus by a bystander effect, it would work.

Overall, there was no effect on the prostate death rate or growth rate in these patients. Vogelzang says it’s common in oncology that great ideas don’t pan out as expected.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.